[Acute intermittent porphyria].
D000255:Adenosine Triphosphate / Q000627:therapeutic use; D000328:Adult; D001205:Ascorbic Acid / Q000627:therapeutic use; D001241:Aspirin / Q000009:adverse effects; D002614:Chelating Agents / Q000627:therapeutic use; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D010205:Pantothenic Acid / Q000627:therapeutic use; D010276:Parasympatholytics / Q000627:therapeutic use; D011164:Porphyrias / Q000188:drug therapy*; D011736:Pyridoxine / Q000627:therapeutic use; D012256:Riboflavin / Q000627:therapeutic use; D013418:Sulfamethazine / Q000009:adverse effects; D013438:Sulfhydryl Compounds / Q000627:therapeutic use; D013835:Thiamine Pyrophosphate / Q000627:therapeutic use; D013997:Time Factors
D002614:Chelating Agents; D005938:Glucocorticoids; D010276:Parasympatholytics; D013438:Sulfhydryl Compounds; D010205:Pantothenic Acid; D013418:Sulfamethazine; D000255:Adenosine Triphosphate; D011736:Pyridoxine; D001205:Ascorbic Acid; D013835:Thiamine Pyrophosphate; D001241:Aspirin; D012256:Riboflavin
Ostraia intermittiruiushchaia porfiriia.